Plazomicin

Summary

Plazomicin (CHEMBL1650559) is an approved small molecule (ATC J01GB14); indicated across 4 conditions including bacterial infectious disease and urinary tract infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01GB14
• Indications: 4 conditions
• Clinical trials: 8
• Chemistry: 592.7 Da · C25H48N6O10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1650559
Name	Plazomicin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	42613186
ATC	J01GB14
Molecular formula	C25H48N6O10
Molecular weight	592.7
InChIKey	IYDYFVUFSPQPPV-PEXOCOHZSA-N

SMILES: C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CNCCO)N)N)NC(=O)[C@H](CCN)O)O

IUPAC name: (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide

Also known as: ACHN-490, Plazomicin, Plazomicina, Plazomicine, PLAZOMICIN

Parent form; salt/anhydrous children: CHEMBL2364623

Patent coverage: 231 distinct patent families (489 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
urinary tract infection	2	MONDO:0100338	EFO:0003103
kidney failure	1	MONDO:0001106	HP:0000083
chronic kidney disease	1	MONDO:0005300	EFO:0003884

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	5
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01970371	PHASE3	COMPLETED	A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
NCT02486627	PHASE3	COMPLETED	A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
NCT01096849	PHASE2	COMPLETED	A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
NCT01034774	PHASE1	COMPLETED	Phase 1 Study to Determine Safety, Blood PK and Lung Penetration
NCT01462136	PHASE1	COMPLETED	PK Study of ACHN-490 Injection in Renally Impaired Subjects
NCT01514929	PHASE1	COMPLETED	A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers
NCT03270553	PHASE1	COMPLETED	A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin
NCT04699656	PHASE1	COMPLETED	Plazomicin Study in ESRD Patients Receiving IHD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kana	CPIC	MT-RNR1		yes

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).